Formulation and evaluation of sustained release ocular inserts of betaxolol hydrochloride using arabinoxylan from Plantago ovata

• Published in: Pakistan journal of pharmaceutical sciences 2021-05, Vol.34 (3(Supplementary)), p.1069-1074
• Main Authors: Sajid Chughtai, Fazal Rahman, Zaman, Muhammad, Khan, Abdul Haleem, Amjad, Muhammad Wahab, Aman, Waqar, Khan, Sajid Mahmood, Ghafoor Raja, Maria Abdul, Nadeem Alvi, Muhammad, Afridi, Maryam, Hanif, Muhammad
• Format: Article
• Language: English
• Subjects: Administration, Ophthalmic; Adrenergic beta-1 Receptor Antagonists - administration & dosage; Adrenergic beta-1 Receptor Antagonists - pharmacokinetics; Alginates; Betaxolol - administration & dosage; Betaxolol - pharmacokinetics; Delayed-Action Preparations; Drug Liberation; Glaucoma, Open-Angle - drug therapy; Glycerol; Plantago; Xylans
• ISSN: 1011-601X
• DOI: 10.36721/PJPS.2021.34.3.SUP.1069-1074.1

The purpose of the current studies was to develop ocular insert of betaxolol hydrochloride (BXH), using arabinoxylan (AX) as a film former. The inserts were prepared by sandwiching I mg of BXH between two films of AX. Six different formulations of ocular inserts were prepared in such a way that first three formulations contained varying concentrations of AX along with glycerol as plasticizer, whereas, rest of the formulations were added with 0.5mg of sodium alginate, sandwiched between two films of AX along with 1mg of BXH. Chemical compatibilities of the ingredients were assessed by using FTIR. Prepared ocular inserts were subjected to various physicochemical characterizations. The dissolution studies showed that ocular inserts containing sodium alginate with the AX showed sustained release effect better than the formulations with AX alone. Addition of sodium alginate resulted in inhibition of sudden release in initial phase and further sustained the release of drug from ocular inserts. Ocular inserts were pH compatible to the eyes as well as there was no interaction among the drug and excipients, suggesting that the selected excipients were suitable for the development of sustained release ocular inserts of BXH.